BELLWAVE-011 (MK-1026-011)

The purpose of this study is to learn more about different treatment approaches for adults diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not received any prior therapy. Researchers are studying an investigational medication called Nemtabrutinib (MK‑1026) and comparing it with existing treatment options used in clinical practice, including ibrutinib and acalabrutinib. This study aims to better understand how these treatments perform relative to one another in areas such as treatment response and how long the disease remains controlled. By gathering this information, researchers hope to expand knowledge about CLL and SLL management and the potential role of different therapeutic strategies. The study is designed as a Phase 3, randomized comparison, meaning participants in the research are assigned by chance to one of the treatment options being studied. The trial follows established scientific methods and oversight procedures to ensure data quality and participant safety.

 

Disclaimer: This summary is provided solely to share information about ongoing scientific efforts in the field of hematologic cancers. It does not invite participation, provide medical advice, or suggest that any investigational medication is safe or effective. Individuals seeking guidance about CLL or SLL should consult their healthcare provider.